A non-government resource for the Medicare community
Powered by Q1Group LLC
A non-government Medicare community resource
  • Menu
  • Home
  • Contact
  • MAPD
  • PDP
  • 2024
  • 2025
  • FAQs
  • Articles
  • Search
  • Contact
  • 2024
  • 2025
  • FAQs
  • Articles
  • Latest Medicare News
  • Search

March 2019 Drug List Updates: Seventy-two (72) new generic drugs added to many Medicare Part D plan formularies.

Category: Monthly Formulary Changes
Published: Apr, 05 2019 01:04:09


As you may know, Medicare Part D prescription drug plans update their plan formularies (drug lists) throughout the plan year and the March 2019 Medicare Part D formulary updates included 198 new drugs, 53 of which are new generic drugs - with a total of 72 new generic equivalents (variations of manufacturer, drug-strength, and packaging).

Below is a full list of the new generics added to the 2019 Medicare Part D (PDP) and Medicare Advantage plan (MAPD) formularies:






Generic Drug Equivalent [Brand-Name Drug]

Number of
PDP
Formularies*

Number of
MAPD
Formularies*

ABIRATERONE ACETATE 250 MG TABLET [ZYTIGA] 55 284
ADAPALENE 0.1% SOLUTION [Plixda] 2 39
ALENDRONATE SODIUM 35 MG TABLET [Fosamax] 62 353
ALENDRONATE SODIUM 70 MG TABLET [Fosamax] 62 353
AMLODIPINE BESYLATE 10 MG TABLET [Norvasc] 62 353
AMLODIPINE BESYLATE 5 MG TABLET [Norvasc] 62 353
AMLODIPINE-BENAZEPRIL 10-40 MG Capsule [Lotrel] 53 347
AMLODIPINE-BENAZEPRIL 5-40 MG Capsule [Lotrel] 53 347
AMPHETAMINE SULFATE 10 MG TABLET [Evekeo] 1 18
AMPHETAMINE SULFATE 5 MG TABLET [Evekeo] 1 18
AZELAIC ACID 15% GEL [Finacea] 26 188
BUPROPION HCL XL 450 MG TABLET ER 24H [Forfivo XL] 3 100
CEFEPIME HCL 1 GM VIAL [Maxipime] 62 353
CEFEPIME HCL 2 GRAM VIAL [Maxipime] 60 351
CLIND PH-BENZOYL PERO 1.2-2.5% GEL W/PUMP [Acanya] 10 49
CLOBAZAM 10 MG TABLET [ONFI] 62 353
CLOBAZAM 2.5 MG/ML Oral Suspension [ONFI] 62 353
CLOBAZAM 20 MG TABLET [ONFI] 62 353
COLESEVELAM HCL 3.75 G PACKET POWD PACK [WelChol] 31 242
CYRED EQ 28 DAY TABLET [Solia] 49 287
DALFAMPRIDINE ER 10 MG TABLET ER 12H [Ampyra] 58 341
DAPTOMYCIN 350 MG VIAL [Cubicin RF] 42 288
DESOXIMETASONE 0.25% SPRAY [Topicort] 6 50
DEXAMETHASONE 10 DAY 1.5 MG TABLET DS PK [ZonaCort 7 Day] 8 89
DEXAMETHASONE 13 DAY 1.5 MG TABLET DS PK [ZonaCort 7 Day] 8 91
DEXAMETHASONE 6 DAY 1.5 MG TABLET DS PK [ZonaCort 7 Day] 8 88
DORZOLAMIDE-TIMOLOL 2%-0.5% DROPERETTE [Cosopt PF] 14 113
DROSP-EE-LEVOMEF 3-0.02-0.451 TABLET [Beyaz] 24 146
ERTAPENEM 1 GRAM VIAL [Invanz] 48 337
FLAC OTIC OIL 0.01% EAR DROPS [Flac] 41 185
HYDROCORTISONE BUTYR 0.1% LOTION [Locoid] 7 81
HYDROMORPHONE HCL ER 12 MG TABLET ER 24H [Exalgo] 4 76
HYDROMORPHONE HCL ER 16 MG TABLET ER 24H [Exalgo] 5 78
HYDROMORPHONE HCL ER 8 MG TABLET ER 24H [Exalgo] 4 76
IMIQUIMOD 3.75% CREAM PUMP CRM MD PMP [Zyclara] 6 105
ITRACONAZOLE 10 MG/ML SOLUTION [Sporanox] 20 128
KETOPROFEN 25 MG CAPSULE [Orudis] 23 173
KETOROLAC 0.4% OPHTH SOLUTION Drops [Acular LS] 62 352
LACTULOSE 10 GM PACKET [Kristalose] 7 63
LEDIPASVIR-SOFOSBUVIR 90-400MG TABLET [Harvoni] 8 103
LEVOFLOXACIN 500 MG/20 ML VIAL [Levaquin] 59 343
LIOTHYRONINE SOD 50 MCG TABLET [Cytomel] 62 353
MESALAMINE 800 MG DR TABLET DR [Asacol HD] 36 258
MINOCYCLINE ER 55 MG TABLET ER 24H [Solodyn] 2 24
MONDOXYNE NL 100 MG CAPSULE [Monodox] 42 228
MONDOXYNE NL 75 MG CAPSULE [NutriDox] 25 100
MORPHINE SULF 10 MG/5 ML Solution [MSIR] 56 333
MORPHINE SULF 20 MG/5 ML Solution [MSIR] 56 334
MORPHINE SULFATE ER 40 MG CAP ER PEL [Kadian] 6 89
NITROFURANTOIN MCR 100 MG CAPSULE [Macrodantin] 62 349
OXYCODONE-ACETAMINOPHEN 10-325 TABLET [Percocet] 62 353
PIOGLITAZONE-GLIMEPIRIDE 30-2 TABLET [Duetact] 20 191
PIPERACIL-TAZOBACT 40.5 GRAM VIAL [Zosyn] 48 307
POTASSIUM CL 10% (20 MEQ/15ML) Liquid [Kay Ciel] 62 353
POTASSIUM CL 20% (40 MEQ/15ML) Liquid [Kaon-CL] 48 315
PRIMIDONE 250 MG TABLET [Mysoline] 62 353
PRIMIDONE 50 MG TABLET [Mysoline] 62 353
PROMETHAZINE-PHENYLEPHRINE SYRUP [Prometh VC Plain] 2 136
PRUDOXIN 5% CREAM (g) [Zonalon] 10 40
QUININE SULFATE 324 MG CAPSULE [Qualaquin] 44 295
SOFOSBUVIR-VELPATASVIR 400-100 TABLET [Epclusa] 8 158
SOTALOL 120 MG TABLET [Sorine] 62 345
TADALAFIL 2.5 MG TABLET [Cialis] 3 61
TADALAFIL 5 MG TABLET [Cialis] 3 62
TELMISARTAN 20 MG TABLET [Micardis] 51 314
TENOFOVIR DISOP FUM 300 MG TABLET [Viread] 62 352
TESTOSTERONE 1.62% (1.25 G) PKT GEL PACKET [AndroGel] 37 241
TESTOSTERONE 1.62% (2.5 G) PKT GEL PACKET [AndroGel] 37 245
TESTOSTERONE 1.62% GEL PUMP GEL MD PMP [AndroGel] 37 240
TRANYLCYPROMINE SULF 10 MG TABLET [Parnate] 62 353
TRETINOIN 0.05% GEL [Atralin] 19 191
VORICONAZOLE 200 MG TABLET [VFEND] 62 353
*The number of formularies counts the unique formularies that offer this medication. As a note, the same formulary can be used by one or many different Medicare Part D plans. The same formulary can be used by both PDP and MAPD plans.



What Could the Addition of New Generic Drugs Mean to You?
  • You may be able to save money by switching from the brand-name drug to its generic equivalent – with your prescriber’s approval and a new prescription. Please note, you will need to look carefully at coverage costs as we have found that many 2019 generics are being offered on the same tier as their brand-name equivalent or the generics do not have a significantly lower retail price.

  • Your brand-name drug may no longer be available if a generic is now available. Based on past experience, you may find that many Medicare Part D plans discontinue coverage for the brand-name drug in the months following the introduction of the generic equivalent. If you have received notice from your Medicare Part D plan that your brand-name medication will be dropped, you should speak with your prescriber to determine if you can take the generic equivalent or if you must continue taking the brand-name drug, you will need to ask your plan for a formulary exception to continue coverage for your brand-name drug. You can click for a chart showing the trends in formulary coverage for some of the more popular Medicare drugs and their generic equivalents.
As a note, both our Formulary Browser (you can view all the drugs covered by a single Medicare prescription drug plan) and our Q1Rx Drug Finder (you can view all the Medicare drug plans covering a single drug) have been updated with the March 2019 Medicare Part D formulary data.








Tips & Disclaimers
  • Q1Medicare®, Q1Rx®, and Q1Group® are registered Service Marks of Q1Group LLC and may not be used in any advertising, publicity, or for commercial purposes without the express authorization of Q1Group.
  • The Medicare Advantage and Medicare Part D prescription drug plan data on our site comes directly from Medicare and is subject to change.
  • Medicare has neither reviewed nor endorsed the information on our site.
  • We provide our Q1Medicare.com site for educational purposes and strive to present unbiased and accurate information. However, Q1Medicare is not intended as a substitute for your lawyer, doctor, healthcare provider, financial advisor, or pharmacist. For more information on your Medicare coverage, please be sure to seek legal, medical, pharmaceutical, or financial advice from a licensed professional or telephone Medicare at 1-800-633-4227.
  • We are an independent education, research, and technology company. We are not affiliated with any Medicare plan, plan carrier, healthcare provider, or insurance company. We are not compensated for Medicare plan enrollments. We do not sell leads or share your personal information.
  • Benefits, formulary, pharmacy network, provider network, premium and/or co-payments/co-insurance may change on January 1 of each year. Our PDPCompare.com and MACompare.com provide highlights of annual plan benefit changes.
  • The benefit information provided is a brief summary, not a complete description of benefits. For more information contact the plan.
  • Limitations, copayments, and restrictions may apply.
  • We make every effort to show all available Medicare Part D or Medicare Advantage plans in your service area. However, since our data is provided by Medicare, it is possible that this may not be a complete listing of plans available in your service area. For a complete listing please contact 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week or consult www.medicare.gov.
    Statement required by Medicare:
    "We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options."
  • When enrolling in a Medicare Advantage plan, you must continue to pay your Medicare Part B premium.
  • Medicare beneficiaries with higher incomes may be required to pay both a Medicare Part B and Medicare Part D Income Related Monthly Adjustment Amount (IRMAA). Read more on IRMAA.
  • Medicare Advantage plans that include prescription drug coverage (MAPDs) are considered Medicare Part D plans and members with higher incomes may be subject to the Medicare Part D Income Related Monthly Adjustment Amount (IRMAA), just as members in stand-alone Part D plans. In certain situations, you can appeal IRMAA.
  • You must be enrolled in both Medicare Part A and Part B to enroll in a Medicare Advantage plan. Members may enroll in a Medicare Advantage plan only during specific times of the year. Contact the Medicare plan for more information.
  • If you are enrolled in a Medicare plan with Part D prescription drug coverage, you may be eligible for financial Extra Help to assist with the payment of your prescription drug premiums and drug purchases. To see if you qualify for Extra Help, call: 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048, 24 hours a day/ 7 days a week or consult www.medicare.gov; the Social Security Office at 1-800-772-1213 between 7 a.m. and 7 p.m., Monday through Friday. TTY users should call, 1-800-325-0778; or your state Medicaid Office.
  • Medicare evaluates plans based on a 5-Star rating system. Star Ratings are calculated each year and may change from one year to the next.
  • A Medicare Advantage Private Fee-for-Service plan (PFFS) is not a Medicare supplement plan. Providers who do not contract with the plan are not required to see you except in an emergency.
  • Disclaimer for Institutional Special Needs Plan (SNP): This plan is available to anyone with Medicare who meets the Skilled Nursing Facility (SNF) level of care and resides in a nursing home.
  • Disclaimer for Dual Eligible (Medicare/Medicaid) Special Needs Plan (SNP): This plan is available to anyone who has both Medical Assistance from the State and Medicare. Premiums, co-pays, co-insurance, and deductibles may vary based on the level of Extra Help you receive. Please contact the plan for further details.
  • Disclaimer for Chronic Condition Special Needs Plan (SNP): This plan is available to anyone with Medicare who has been diagnosed with the plan specific Chronic Condition.
  • Medicare MSA Plans combine a high deductible Medicare Advantage Plan and a trust or custodial savings account (as defined and/or approved by the IRS). The plan deposits money from Medicare into the account. You can use this money to pay for your health care costs, but only Medicare-covered expenses count toward your deductible. The amount deposited is usually less than your deductible amount, so you generally have to pay out-of-pocket before your coverage begins.
  • Medicare MSA Plans do not cover prescription drugs. If you join a Medicare MSA Plan, you can also join any separate (stand-alone) Medicare Part D prescription drug plan
  • There are additional restrictions to join an MSA plan, and enrollment is generally for a full calendar year unless you meet certain exceptions. Those who disenroll during the calendar year will owe a portion of the account deposit back to the plan. Contact the plan provider for additional information.
  • Medicare beneficiaries may enroll through the CMS Medicare Online Enrollment Center located at www.medicare.gov.
  • Medicare beneficiaries can file a complaint with the Centers for Medicare & Medicaid Services by calling 1-800-MEDICARE 24 hours a day/7 days or using the medicare.gov site. Beneficiaries can appoint a representative by submitting CMS Form-1696.